Osocimab, formerly known as BAY 1213790, represents a unique monoclonal antibody currently undergoing clinical development for the management of multiple hematologic tumors. This agent selectively targets CD38, a cell https://gretaooet745495.blog-gold.com/58347870/osocimab-a-deep-examination-into-bay-1213790-and-its-outlook